Navigation Links
PTC Therapeutics Announces Achievement of Major Milestone in Schering-Plough Hepatitis C Collaboration
Date:8/10/2009

SOUTH PLAINFIELD, N.J., Aug. 10 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced that it has reached a major research milestone in its collaboration with Schering-Plough Corporation (NYSE: SGP) receiving a $2 million payment in connection with the designation of a development candidate for the treatment of hepatitis C virus (HCV) infection.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010919/PTCLOGO )

The collaboration began in March of 2006 based on PTC's HCV efforts that were initiated using the GEMS(TM) technology (Gene Expression Modulation through Small Molecules). Under the terms of the collaboration, PTC and Schering-Plough are conducting a joint research program and Schering-Plough will be responsible for development and commercialization efforts worldwide. Schering-Plough made an upfront payment of $12 million in 2006 and PTC may earn additional milestone payments if specific development, regulatory and commercial goals are achieved. Total payments to PTC could exceed $200 million. Schering-Plough will receive exclusive worldwide commercialization rights for any approved products and pay PTC royalties on worldwide net sales.

"This important milestone represents the third development candidate arising from our novel technologies and research efforts and demonstrates PTC's ability to identify potential treatments across multiple therapeutic areas. We are very gratified to reach this milestone with Schering-Plough, a recognized leader in antiviral research and a wonderful partner to PTC," said Stuart Peltz, Ph.D., president and CEO of PTC Therapeutics. "Hepatitis C is an area of great unmet medica
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Cell Therapeutics Second Quarter Net Loss Decreases 54%; Pixantrone NDA Submitted to the FDA for Approval
2. The Breast Cancer Therapeutics Market in Australia
3. Amicus Therapeutics Announces Second Quarter 2009 Financial Results
4. Orexigen(R) Therapeutics to Speak at Canaccord Adams Global Growth Conference
5. Nile Therapeutics, Inc. Announces Dosing of First Patient in Phase 2 Study of CD-NP for the Treatment of Acute Heart Failure
6. Nektar Therapeutics to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference in New York City
7. Stemline Therapeutics CEO to Present at IBCs New Frontiers in Cancer Drug Development Conference
8. Cornerstone Therapeutics Announces Closing of Chiesi Transaction
9. Amicus Therapeutics Announces Second Quarter 2009 Financial Results Release Date
10. PTC Therapeutics Initiates Phase 2 Clinical Trial of PTC299 in Patients with Neurofibromatosis Type 2
11. Orexigen(R) Therapeutics Announces Full Exercise of Overallotment Option by Underwriters
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... Earth, MN (PRWEB) June 19, 2013 ... of abuse tests, today announced that it has received ... to market and sell its DrugCheck® NxStep Onsite ... allows use of the rapid screening device in near-patient ... Onsite Drug Screen Cup received Health Canada Class III ...
(Date:6/18/2013)... 18, 2013 Tabletop SEMs are inexpensive ... but have limited performance and capability such as small ... SEMs would normally provide better imaging performance and more ... and have a higher cost of maintenance. The ... between these two types of SEM product, offering competitive ...
(Date:6/18/2013)... -- China Cord Blood Corporation (NYSE: CO ... cord blood collection, laboratory testing, hematopoietic stem cell processing, ... unaudited financial results for the fourth quarter and full ... Fourth Quarter of Fiscal 2013 Highlights ... 2013 increased by 33.3% to RMB133.0 million ($21.4 million) ...
(Date:6/18/2013)... Los Angeles, CA (PRWEB) June 18, 2013 (PRWEB) ... of construction’s #1 time and attendance system in ... transfer software that shares employee data and payroll ... , AccountLinx Plus automates ExakTime software ... applications. The software imports employee data from a ...
Breaking Biology Technology:Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 2Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 3Nanounity Introduces the Pemtron Range of Compact Scanning Electron Microscopes 2Nanounity Introduces the Pemtron Range of Compact Scanning Electron Microscopes 3China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 2China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 3China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 4China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 5China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 6China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 7China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 8China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 9China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 10China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 11China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 12China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 13ExakTime Introduces AccountLinx Plus 2
... System and GE Medical Systems recently signed a five-year ... medical field. The Wheaton Franciscan System, a Catholic heath ... GE Medical System s Performance Solutions; a portfolio ... care customers in addition to the purchase of imaging ...
... Wis. -- Bruker AXS Inc., a provider of X-ray ... that it has been selected to participate in the ... The project is half-funded by the Dutch government, and ... expects to receive approximately $950,000 in matching funds. ...
... , a provider of integrated data solutions for ... Friday. The service allows customers to meet with ... and other online collaborations. , ,Norlight's Guardian ... visual benefits of Web collaboration. Using a Web-based ...
Cached Biology Technology:
(Date:6/17/2013)... may help delay early onset of puberty in girls, ... Monday at The Endocrine Society,s 95th Annual Meeting in ... the ages of 10 and 14. Boys undergo these ... age. Precocious puberty is diagnosed in girls when sexual ... it is diagnosed when these changes occur before age ...
(Date:6/17/2013)... be the topics under discussion during the E3 ... third consecutive year, this will be a unique ... among members of Academy, Business, Educators, Entrepreneurs, Innovators, ... Elisa Martn Garijo (IBM South Europe), Chris Zegras ... O,Donovan (Hovione), among others. E3 Forum - Education, ...
(Date:6/16/2013)... for female sex workers in India reduce rates of ... University of Toronto study has found. , ... in the southern states of Andhra Pradesh, Karnataka, Maharashtra ... Jha from U of T,s Dalla Lana School of ... Health Research (CGHR), examined the impact of prevention among ...
Breaking Biology News(10 mins):Vitamin D supplementation may delay precocious puberty in girls 2'E3 Forum -- Education, Employment & Entrepreneurship on a Global context' 2HIV prevention among female sex workers in India reduces HIV and syphilis 2
... Thomas C. Quinn, M.D., a Johns Hopkins physician and scientist, ... years leading major efforts to combat HIV and AIDS throughout ... confront the rapid "feminization" of the AIDS pandemic. , Quinn, ... investigator at the National Institute of Allergy and Infectious Disease, ...
... people, naturally produce disease-fighting chemicals, called antimicrobial peptides, ... some disease-causing bacteria have evolved antimicrobial detectors. The ... a warning signal. This alarm sets off a ... University of Washington (UW) and McGill University researchers ...
... of the three-dimensional terrain of a synapse -- the ... the brain and nervous system. The "nano-map," which shows ... or one-billionth of a meter, has already proven its ... , Using the map as a guide, the research ...
Cached Biology News:AIDS expert says global strategy needed to combat feminization of HIV/AIDS 2AIDS expert says global strategy needed to combat feminization of HIV/AIDS 3Bacteria recognize antimicrobials, respond with counter-defenses 2The synapse is a shotgun 2The synapse is a shotgun 3
...
... potent inhibition of RNase A-type ribonucleases Product ... of nonhuman origin that binds noncovalently and ... A, B, and C). It does not ... U2, or CL3. QIAGEN RNase Inhibitor inhibits ...
...
... Radiochemical Purity is >95%\nNEN Radiolabeled Ligands\n\nReceptor-related ... continual availability of new radiolabeled ligands selected ... offers a wide range of products and ... including over 400 state-of-the-art radioligands. If you ...
Biology Products: